Strata Critical Medical Inc

Análisis de la acción Strata Critical Medical Inc (SRTA)

$5.970

-0.193 (-3.24%)Al cierre

Loading chart…
High
6.150
Open
6.140
VWAP
6.00
Vol
564.47K
Mkt Cap
Low
5.885
Amount
3.39M
EV/EBITDA, TTM
-116.51

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. Its other clinical services include cardiac care and others.

AI analysis of Strata Critical Medical Inc (SRTA)

buy

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong performance and positive outlook. The current price is $5.97, significantly lower than the analyst price targets of $8 and $11.50, indicating a potential upside of 33.5% to 93.5%. The company reported a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and raised its revenue guidance for 2026 to between $285 million and $295 million. However, the main risk is the negative net income reported for Q2 2026, amounting to -$10.52 million, which could affect investor sentiment.

Métricas de valoración

The current forward P/E ratio for Strata Critical Medical Inc (SRTA) is 138.89, compared to its 5-year average forward P/E of 57.62.

Forward P/E

Overvalued
5Y Average P/E
57.62
Current P/E
138.89
Sobrevalorada
137.47
Infravalorada
-22.23

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
117.41
Current EV/EBITDA
-116.51
Sobrevalorada
383.05
Infravalorada
-148.24

Forward P/S

Overvalued
5Y Average P/S
1.41
Current P/S
1.67
Sobrevalorada
1.66
Infravalorada
1.17

Whales holding SRTA

T

Third Point LLC

+ HoldingSRTA

+2.06%

3M Return

Cronología de eventos

2026-05-06 (ET)

07:40:00

Strata Adjusts FY26 EBITDA Guidance to $29M-$33M

07:40:00

Company Reports Q1 Revenue of $67.38M, Exceeding Expectations

2026-03-03 (ET)

07:10:00

Raises EBITDA Outlook to $29M-$33M

07:10:00

Will Heyburn: Company Aims for 30% Annual EBITDA Growth

2026-02-05 (ET)

08:50:00

Strata Critical Medical Enters $30M Credit Agreement with JPMorgan

Noticias

SRTA FAQ — answered by Alphio AI

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. Its other clinical services include cardiac care and others. It operates in the Industrials sector.

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong performance and positive outlook. The current price is $5.97, significantly lower than the analyst price targets of $8 and $11.50, indicating a potential upside of 33.5% to 93.5%. The company reported a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and raised its revenue guidance for 2026 to between $285 million and $295 million. However, the main risk is the negative net income reported for Q2 2026, amounting to -$10.52 million, which could affect investor sentiment.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis